Figure 4.
![Figure 4. Overall survival from 6 months after second transplantation by study (TT2 with consolidation chemotherapy vs dexamethasone [DEX] vs TT1) and presence or absence of cytogenetic abnormalities (CAs). TT2 patients with baseline CAs, treated with chemotherapy for consolidation, had superior OS compared with those receiving DEX for consolidation. OS was similar for TT2 patients without CAs, regardless of consolidation therapy. OS for TT1 patients with CAs was similar to OS for TT2 patients receiving DEX.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/107/7/10.1182_blood-2005-10-4084/5/zh80070693400004.jpeg?Expires=1725326341&Signature=CPTp~st8nD81-79O~-3b4KTNp6d2JvVkImdeOC8r4Lu3TbAJ~g40PSu4X8P0XrM~5A-eMvIDIgWa9VzwFidhJ72CQ~eI5V7APb8f8WBRrdIwnIJrNa-FHUKfqAwyZTAsnjbjooAj-JVX2h6pl4dT8A5c7PEfTkoL9-vDIRVPrsf1llqayVKOWGYW5KPr01e0XZY~PzkkzNCKsbB0IS4wvZ3i6AzQUlZ7q9jZYaVeJ-hQLGyiYYxN~Y2n7levwokwgNfpmb7XqNkQwttN~wpfz9~DYM25jsGsh9Jb5JaPymmc2l7BMoH7Imn1sbSjyR-TjrRGhDdasGxrT07psjEdCg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Overall survival from 6 months after second transplantation by study (TT2 with consolidation chemotherapy vs dexamethasone [DEX] vs TT1) and presence or absence of cytogenetic abnormalities (CAs). TT2 patients with baseline CAs, treated with chemotherapy for consolidation, had superior OS compared with those receiving DEX for consolidation. OS was similar for TT2 patients without CAs, regardless of consolidation therapy. OS for TT1 patients with CAs was similar to OS for TT2 patients receiving DEX.
